Prescient Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTX.AX research report →
Price Chart
About the company
Prescient Therapeutics Limited (PTX. AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several clinical trials: Phase 2a for HER2-negative breast cancer, Phase 1B/2 for acute myeloid leukemia that has relapsed or is resistant to treatment, and Phase 1b for ovarian cancer that is recurrent, persistent, or resistant to platinum-based therapies.
- CEO
- James McDonnell
- IPO
- 1999
- Employees
- 3
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on PTX.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $79.92M
- P/E
- -7.52
- PEG
- 0.50
- P/S
- 25.71
- P/B
- 4.49
- EV/EBITDA
- -7.02
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -323.82%
- Net Margin
- -285.08%
- ROE
- -62.49%
- ROIC
- -33.53%
Latest fiscal year · YoY change
- Revenue
- $4.36M+17.4%
- Gross Profit
- $4.36M+17.4%
- Op Income
- $-7,535,758
- Net Income
- $-7,322,531+11.1%
- EPS
- $-0.01+10.8%
- OCF Growth
- +2.1%
- FCF Growth
- +2.1%
- 52W High
- $0.13
- 52W Low
- $0.04
- 50D MA
- $0.08
- 200D MA
- $0.07
- Beta
- 0.77
- RSI (14)
- 42
- Avg Volume
- 946.29K
No earnings-call transcripts are available for PTX.AX yet.
- Free Float
- 88.3%
- Shares Outstanding
- 1.05B
- Float Shares
- 928.97M
Our PTX.AX coverage
Recent articles, reports, and earnings notes.
No research on PTX.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PTX.AX report →Dow Jones, S&P 500 gain on rate cut hopes as shutdown cancels key inflation, jobs reports
proactiveinvestors.com · Nov 21
Prescient secures EMA Orphan Drug Designation for PTX-100 in CTCL
proactiveinvestors.com · Nov 19
'Church-tech' firm Gloo Holdings makes $600m stock market debut
proactiveinvestors.com · Nov 19
Evion Group welcomes Madagascan Government commitment to mining industry
https://www.proactiveinvestors.com · Jan 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.